The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | The need for novel agents to treat patients with MCL who have relapsed after targeted therapy
Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the unmet needs in treating relapsed/refractory (R/R) mantle cell lymphoma (MCL), highlighting the limited durability of targeted therapies due to multiple tumor growth pathways. He emphasizes the need for continued innovation, particularly in molecular biology, to achieve profound molecular responses and potentially cure MCL. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
